Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. It operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LYSOVETA brand; and marine-origin DHA omega-3 from microalgae under the Revervia brand name, as well as advanced phospholipid technology under PL+ name. The Consumer Health Products segment sells processed and packaged krill, fish, and plants derived raw materials to retailers in the United States. The Emerging Business segment offers krill oil under Kori brand name. The company provides protein solutions under the Understory brand; biostimulants under KRBNX brand; and a therapeutic candidate based on omega-3 to manage and treat cardiometabolic diseases under CaPre brand name, as well as delivers circular products utilizing recycled industrial and marine plastic waste under AION name. Aker BioMarine ASA was founded in 2006 and is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker ASA.
Часто задаваемые вопросы
В каком секторе работает Aker Biomarine AS (AKBM)?
Aker Biomarine AS относится к сектору Товары повседневного спроса.
Какова текущая цена акций Aker Biomarine AS (AKBM)?
По последним данным, цена акций Aker Biomarine AS составляет 126,00 NOK, предыдущее закрытие — 128,60 NOK. За последнюю торговую сессию акции Aker Biomarine AS снизились на -2,60 NOK, что соответствует падению на -2,02%.
Выплачивает ли Aker Biomarine AS (AKBM) дивиденды?
Нет, Aker Biomarine AS не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Aker Biomarine AS (AKBM)?
У компании Aker Biomarine AS бета 0.293, что указывает на более низкую волатильность по сравнению с рынком в целом.